Published July 16, 2021
| Version v1
Journal article
Open
The Type I interferon antiviral gene program is impaired by lockdown and preserved by caregiving
Creators
- 1. University of California
- 2. University of Chicago
Description
Previous research has linked perceived social isolation (loneliness) to reduced antiviral immunity, but the immunologic effects of the objective social isolation imposed by pandemic "shelter in place" (SIP) policies is unknown. We assessed the immunologic impact of SIP by relocating 21 adult male rhesus macaques from 2,000-m2 field cage communities of 70 to 132 other macaques to 2 wk of individual housing in indoor shelters. SIP was associated with 30% to 50% reductions in all circulating immune cell populations (lymphocytes, monocytes, and granulocytes), down-regulation of Type I interferon (IFN) antiviral gene expression, and a relative up-regulation of CD16− classical monocytes. These effects emerged within the first 48 h of SIP, persisted for at least 2 wk, and abated within 4 wk of return to social housing. A subsequent round of SIP in the presence of a novel juvenile macaque showed comparable reductions in circulating immune cell populations but reversal of Type I IFN reductions and classical monocyte increases observed during individual SIP. Analyses of lymph node tissues showed parallel up-regulation of Type I IFN genes and enhanced control of viral gene expression during juvenile-partnered SIP compared to isolated SIP. These results identify a significant adverse effect of SIP social isolation on antiviral immune regulation in both circulating immune cells and lymphoid tissues, and they suggest a potential behavioral strategy for ameliorating gene regulatory impacts (but not immune cell declines) by promoting prosocial engagement during SIP. © 2021 National Academy of Sciences. All rights reserved.
Data availability
Files
cole-et-al-2021-the-type-i-interferon-antiviral-gene-program-is-impaired-by-lockdown-and-preserved-by-caregiving.pdf
Files
(2.2 MB)
| Name | Size | Download all |
|---|---|---|
|
Article md5:b065d98770f4b71a1f9b8766c3ef518f |
898.7 kB | Preview Download |
|
md5:e651d85ceafe052bc44c843fc8060c9c
|
1.3 MB | Preview Download |
Additional details
Identifiers
- DOI
- 10.1073/pnas.2105803118
- Other
- oai:uchicago.tind.io:9607
Funding
- National Institutes of Health
- R01 AG033590
- National Institutes of Health
- R01 AG043404
- National Institutes of Health
- P51 OD011107